As its “Immune Cell Atlas” Gets Better, Immunai Announces a $215 Million Series B
Immunai is funded well. By February 2021, the company that started creating an immune system atlas in 2018 had raised $80 million. The company announced a $215 million Series B.
Immunai is collecting clinical immunological data. It combines genetic information with epigenetic changes and proteomics to map the immune system. This round, led by Koch Disruptive Technologies, brings the company’s total funding to $295 million.
